EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis

Domenico Albano, Stephane Chauvie, Alessio Rizzo, Francesco Bertagna, Beatrice Casadei, Umberto Vitolo, Alessandra Tucci, Pier Luigi Zinzani, Luca Guerra

Clinical Lymphoma Myeloma and Leukemia · 2026-08 · 26 (8) · 491-510.e1

DOI: 10.1016/j.clml.2026.06.008 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-08. Verfasst von Domenico Albano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, University of Brescia, Brescia, Italy; Nuclear Medicine Department, ASST Spedali Civili di Brescia, Brescia, Italy. Electronic addr…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prognostic value of interim 18F-fluorodeoxyglucose positron emission tomography/computed tomography (iPET/CT) in diffuse large B-cell lymphoma (DLBCL) remains a subject of debate due to inconsistencies in timing and interpretation. This updated systematic review and meta-analysis aimed to investigate the ability of iPET to predict progression-free survival (PFS). A systematic literature search was conducted across PubMed/MEDLINE, Cochrane, and Embase databases until December 31, 2025. Studies investigating the prognostic value of iPET/CT for PFS in DLBCL were included. Data on complete metabolic response (CMR) rates and hazard ratios (HR) for PFS were pooled using a random-effects model. The pooled CMR rate across 66 articles (9.335 patients) was 67.2% (95% confidence interval [CI]. 63.9%-70.4%), though significant variability (38%-94%) and extreme heterogeneity were observed (I2 = 92.45%). Subgroup analysis confirmed that timing influenced these rates: CMR was 63.3% after 2 cycles vs. 74.4% after 4 cycles. Regarding PFS, the pooled HR across 63 studies was 3.05 (95% CI, 2.63-3.54) for a positive iPET. Notably, utilizing a Deauville score (DS) threshold of 5 alone yielded a significantly higher pooled HR of 5.72 (95% CI, 4.35-7.51) with more moderate heterogeneity (I2 = 40.7%). In contrast, the prognostic effect of ΔSUV66% was weaker, with a pooled HR of 1.83. Scans performed after 4 cycles (iPET4, HR: 3.20) showed slightly stronger prognostic performance than those after 2 cycles (iPET2, HR: 2.84). Interim PET/CT, particularly when utilizing the DS 5 threshold, is a strong biomarker for identifying high-risk DLBCL patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffusePositron Emission Tomography Computed TomographyFluorodeoxyglucose F18HumansPrognosis

Stichwörter der Autor:innen

DLBCLNuclear medicinePositron emission tomography

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Nuclear Medicine, University of Brescia, Brescia, Italy; Nuclear Medicine Department, ASST Spedali Civili di Brescia, Brescia, Italy. Electronic address: doalba87@libero.it.
  • Division of Medical Physics, Santa Croce e Carle Hospital, Cuneo, Italy.
  • Department of Nuclear Medicine, FPO-IRCCS Candiolo Cancer Institute, Turin, Italy.
  • Nuclear Medicine, University of Brescia, Brescia, Italy; Nuclear Medicine Department, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Institute of Hematology "L. e A. Seràgnoli", Bologna, Italy.
  • Candiolo Cancer Institute, FPO-IRCCS Candiolo, Turin, Italy.

Zitieren

APA

Albano, D., Chauvie, S., Rizzo, A., Bertagna, F., Casadei, B., Vitolo, U., Tucci, A., Zinzani, P. L., & Guerra, L. (2026). The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma and Leukemia, 26(8), 491-510.e1. https://doi.org/10.1016/j.clml.2026.06.008

Vancouver

Albano D, Chauvie S, Rizzo A, Bertagna F, Casadei B, Vitolo U, et al. The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma and Leukemia. 2026;26(8):491-510.e1. doi:10.1016/j.clml.2026.06.008

BibTeX
@article{Albano2026,
  author = {Albano, Domenico and Chauvie, Stephane and Rizzo, Alessio and Bertagna, Francesco and Casadei, Beatrice and Vitolo, Umberto and Tucci, Alessandra and Zinzani, Pier Luigi and Guerra, Luca},
  title = {The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {8},
  pages = {491--510.e1},
  doi = {10.1016/j.clml.2026.06.008}
}
Kostenlos starten →